Intraarticular triamcinolone hexacetonide, stanozolol, Hylan G-F 20 and platelet concentrate in a naturally occurring canine osteoarthritis model.

Abstract

Osteoarthritis (OA) is a disease transversal to all mammals, a source of chronic pain and disability, a huge burden to societies, with a significant toll in healthcare cost, while reducing productivity and quality of life. The dog is considered a useful model for the translational study of the disease, closely matching human OA, with the advantage of a faster disease progression while maintaining the same life stages. In a prospective, longitudinal, double-blinded, negative controlled study, one hundred (N = 100) hip joints were selected and randomly assigned to five groups: control group (CG, n = 20, receiving a saline injection), triamcinolone hexacetonide group (THG, n = 20), platelet concentrate group (PCG, n = 20), stanozolol group (SG, n = 20) and hylan G-F 20 group (HG). Evaluations were conducted on days 0 (T0, treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post-treatment, consisting of weight distribution analysis and data from four Clinical Metrology Instruments (CMI). Kaplan-Meier estimators were generated and compared with the Breslow test. Cox proportional hazard regression analysis was used to investigate the influence of variables of interest on treatment survival. All results were analyzed with IBM SPSS Statistics version 20 and a significance level of p < 0.05 was set. Sample included joints of 100 pelvic limbs (of patients with a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. Joints were graded as mild (n = 70), moderate (n = 20) and severe (n = 10) OA. No differences were found between groups at T0. Kaplan-Meier analysis showed that all treatments produced longer periods with better results in the various evaluations compared to CG. Patients in HG and PCG took longer to return to baseline values and scores. A higher impact on pain interference was observed in THG, with a 95% improvement over CG. PCG and HG experienced 57-81% improvements in functional evaluation and impairments due to OA, and may be a better options for these cases. This study documented the efficacy of several approaches to relieve OA clinical signs. These approaches varied in intensity and duration. HG and PCG where the groups were more significant improvements were observed throughout the follow-up periods, with lower variation in results.

• Authors: J C Alves, A Santos, P Jorge, C Lavrador, L Miguel Carreira
• Journal: Scientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 3118 (02 04 2021) ISSN: 2045-2322 [Electronic] England
• PMID: 33542412 (Publication Type: Journal Article, Randomized Controlled Trial, Veterinary)

Chemical References

• Anti-Inflammatory Agents
• Hyaluronic Acid
• hylan
• Stanozolol
• Triamcinolone Acetonide
• triamcinolone hexacetonide

Topics

• Animals
• Dogs
• Female
• Male
• Anti-Inflammatory Agents (therapeutic use)
• Blood Platelets (chemistry)
• Dog Diseases (mortality, pathology, physiopathology, therapy)
• Forelimb
• Hindlimb
• Hyaluronic Acid (analogs & derivatives, therapeutic use)
• Osteoarthritis (mortality, pathology, therapy, veterinary)
• Pain (drug therapy, mortality, pathology, veterinary)
• Pain Management
• Proportional Hazards Models
• Prospective Studies
• Severity of Illness Index
• Stanozolol (therapeutic use)
• Triamcinolone Acetonide (analogs & derivatives, therapeutic use)
• Working Dogs